Retroviral vectors integrate into the target cell genome in a stable manner and therefore offer the potential for permanent correction of the genetic diseases that affect the liver. These vectors, however, usually require cell division to occur in order to allow provirus entry into the nucleus. We have explored clinically acceptable methods to improve the efficiency of retroviral gene transfer to the liver, which avoid the need for liver damage. Tri-iodothyronine (T3) and recombinant hepatocyte growth factor have previously been used to induce hepatocyte proliferation in rat livers and allow in vivo retroviral gene transfer. We investigated the combined effects of these growth factors, with their differing mechanisms of action, on hepatocyte proliferation in vivo and assessed their effectiveness in priming cells for retroviral
Introduction
Hepatic gene therapy has the potential to correct a number of metabolic diseases such as familial hypercholesterolaemia, alpha-1-antitrypsin deficiency or Crigler Najjar syndrome, reflecting deficiencies in hepatocyte function due to abnormalities of membrane receptors, 1 protein secretion 2 and transcellular transport, respectively. 3 For permanent genetic correction of such diseases it is desirable for the therapeutic gene construct to be expressed life-long which is most effectively achieved by stable integration into the target cell genome.
Modified Moloney murine leukaemia virus (MoMLV) retroviral vectors are well characterised gene therapy vectors. 4 They integrate into the target cell genome in a stable manner and therefore offer the potential for permanent gene correction. However, they require the target cells to be mitotically active for successful integration to occur. [5] [6] [7] The normal adult liver is mitotically quiescent and therefore resistant to transduction with (MoMLV) gene transfer. During the phase of hepatocyte proliferation retrovirus was administered via either the portal or tail vein. Acting synergistically, T3 and a truncated form of recombinant hepatocyte growth factor (dHGF) induced 30% of hepatocytes in normal rat liver to enter DNA synthesis at 24 h. This increased proliferation enabled the liver to be transduced in vivo by retroviral vectors via either the portal or peripheral venous system, achieving transduction efficiencies of 6.9 ± 1.6% and 4.3 ± 0.4% respectively. Thus, the liver can be simply and conveniently transduced in vivo with integrating vectors, introduced via the peripheral venous system during a wave of growth factor-induced proliferation, pointing the way to clinically applicable gene transfer techniques. Gene Therapy (2000) 7, 784-789. retroviral vectors. Lentivirus-based vectors have been developed which can transduce mitotically quiescent target cells in vivo but concerns exist regarding their safety. 8 The original technique of inducing hepatocyte proliferation before in vivo retroviral gene transfer involved performing a partial hepatectomy (PH). During the resultant regeneration phase the liver can be efficiently transduced with retroviral vectors, achieving hepatocyte transduction efficiencies of up to 35% following a single injection of vector. [9] [10] [11] [12] Unfortunately, PH is a clinically unacceptable technique. Another approach has been to occlude a branch of the portal vein. This leads either to apoptosis or atrophy of the hepatocytes within the portaprival lobe and compensatory proliferation within the other lobes of the liver, permitting retroviral transduction of the proliferating hepatocytes. Non-surgical techniques for inducing liver proliferation have been sought. Lieber et al 14, 15 have used adenoviral vectors to transduce rat liver in vivo with the urokinase gene. The liver transiently expressed urokinase, which resulted in significant liver damage. During the ensuing regenerative response the liver was efficiently transduced with a retroviral vector.
Growth factors have been utilised to induce hepatocyte proliferation without preceding liver damage, enabling retroviral transduction. In particular, we demonstrated that a single T3 injection could induce DNA synthesis in approximately 10% of rat hepatocytes at 24 h and portal injection of a retrovirus encoding a reporter gene transduced 1.3% of hepatocytes. 16 KGF administration to mice has resulted in transduction of 1.2% of hepatocytes, 17 and the hepatocyte proliferative response to KGF has been boosted by co-administration of HGF. 18 HGF given as five intra-portal injections before retroviral administration produced hepatic transduction efficiencies of 1.3%. 19 More efficient transduction of the murine liver has been achieved with HGF but this required a 5 day infusion of both the growth factor and the retrovirus. 20 Undoubtedly the higher proliferation level achieved after PH in comparison with growth factor administration is partly responsible for the disparity in transduction efficiency achieved after these two different approaches. However, the post two-thirds hepatectomy liver contains only a third of the number of hepatocytes found in the intact liver. Therefore the disparity in transduction efficiencies in terms of absolute numbers of hepatocytes is less pronounced. Manoeuvres that increase proliferation levels further in the intact liver, even modestly, may have the potential to allow transduction of even greater numbers of hepatocytes by retroviral vectors.
An alternative approach to increase the hepatic transduction efficiency is to increase the retroviral infectivity. We have previously shown that the infectivity of amphotropic retroviral vectors can be increased by the addition of the cationic liposome DiOctadecylamidoGlycylSpermine (DOGS) to the retroviral vector to form a vectorliposome complex. This enabled a four-fold increase in the in vivo transduction efficiency of the post-hepatectomy liver. 12 In this study we combined the administration of two growth factors with disparate intracellular mechanisms to induce hepatocyte proliferation in the intact liver and enable transduction with the amphotropic virus vector TELCeB/AF-7 21 complexed with the cationic liposome DOGS.
Results

Induction of hepatocyte proliferation
We first characterised the hepatic proliferative response to the administration of single growth factors, and then proceeded to analyse the effect of the combined action of T3 and dHGF.
An initial dose response experiment identified the dose of dHGF that caused maximum hepatocyte proliferation at 24 h. A dose of 1 mg/kg dHGF was found to be maximally effective at producing hepatocyte proliferation following a single tail vein administration. The majority of the labelled hepatocytes were in the periportal and midzonal regions (Figure 1a) . To establish the time at which maximum hepatocyte DNA synthesis occurred following dHGF administration, a single injection of dHGF (1 mg/kg i.v.) was given between 9 and 10 am; groups of three animals were killed at 6, 9, 12, 15, 18, 24 and 30 h and BrdU was given 1 h before death. The maximum hepatocyte labelling was of 8.9 ± 2.9% at 18 h following dHGF administration (Figure 1b) .
We have previously demonstrated that T3 is a simple and effective means of inducing hepatocyte proliferation within the intact rat liver. 16 Following a single injection of T3 (4 mg/kg) approximately 10% of hepatocytes are induced into S-phase, with a maximal effect at 24 h. In contrast to dHGF, following T3 administration the BrdU labelled hepatocytes are predominantly found in the mid-zonal region ( Figure 2 ).
To determine whether the growth factors induced hepatocyte proliferation synergistically, three groups of four rats received either one of the growth factors (T3 4 mg/kg at 0 h), dHGF (1 mg/kg at 6 h), or a combination of both growth factors; a control group of three rats received an injection of the growth factor diluents only. All animals received BrdU at 23 h and were killed at 24 h. The combined administration of both growth factors was the most effective means of inducing hepatocyte proliferation with 30.6 ± 4.4% of hepatocytes in S-phase at 24 h (Figure 3a and b) . Furthermore, the combined administration did act in a synergistic manner, ie the proliferation seen following combined growth factor admin- Retroviral transduction of the intact proliferative rat liver (portal vein administration) Three groups of four rats received an administration of either a single growth factor (T3, or dHGF) or a combination of the two; a control group of three rats were injected with the growth factor diluents only. T3 (4 mg/kg) was given at 0 h and dHGF (1 mg/kg) at 6 h. At 24 h all rats were injected intraportally with 1 ml of TELCeB/AF-7/DOGS complex during temporary hepatic artery and portal vein occlusion; they were all killed 9 days following vector administration. If the liver was primed by a single growth factor then between 1.2 ± 0.4% and 2.3 ± 0.5% of hepatocytes were transduced (Figure 4) . Following dHGF administration the transduced hepatocytes were, as expected, predominantly in the periportal and mid-zonal regions. After T3 administration the transduced hepatocytes were mostly in the mid-zonal region. However, following the combined administration of both growth factors then the proportion of hepatocytes transduced rose to 6.9±1.6 % and these were found throughout most of the liver parenchyma apart from the perivenular zone.
Retroviral transduction of the intact proliferative liver (peripheral vein administration)
We also investigated if the retroviral construct could be administered by the more clinically acceptable intravenous route during liver hyperplasia and still effectively transduce the liver. Given that the hepatocytes enter the cell cycle in a semi-synchronous manner following combined growth factor administration, so that cell replication was occurring over several hours, we reasoned that multiple administrations of the vector would increase the efficiency of transduction.
Ten rats were injected with T3 (4 mg/kg) at 0 h followed by dHGF (1 mg/kg) at 6 h. A group of five rats (group A) received an injection of 1 ml TELCeB/AF-7/DOGS complex via the tail vein at 24 h. The second group of rats (group B) received two 0.5 ml injections of TELCeB/AF-7/DOGS complex at 18 and 24 h; all rats were killed on day 10. On average 1.2 ± 0.38% and 2.3 ± 0.45% of hepatocytes were transduced from groups A and B, respectively (P Ͻ 0.05), illustrating an increase in transduction efficiency by dividing the administration of vector during a period of hepatocyte proliferation.
To maximise the hepatic transduction efficiency following peripheral vein vector administration, three groups of four rats received either T3 (4 mg/kg at 0 h), dHGF (1 mg/kg at 6 h), or both growth factors. Two control rats were injected with growth factor diluent only. All rats received three tail vein injections of 1 ml of the TELCeB/AF-7/DOGS complex at 18, 24 and 30 h and were killed on day 10. Animals that had received both growth factors before the vector administration had the highest levels of transduction with 4.3 ± 0.4% of their hepatocytes expressing the ␤-galactosidase gene ( Figure 5 ).
Discussion
Permanent correction of a metabolic disease requires the stable integration of the therapeutic gene into the host genome. There are a number of gene delivery systems capable of transducing the liver in vivo but to date only retroviral and adeno-associated vectors have the ability to integrate into the host genome. 22 Retroviral vectors are the most widely characterised vectors for in vivo gene delivery and can carry up to 8 kb of therapeutic DNA, but most require cells of the target organ to be mitotically active at the time of transduction. This has suggested the use of clinically undesirable methods of inducing hepatocyte proliferation such as partial hepatectomy [9] [10] [11] [12] and urokinase gene administration 14, 15 before retroviral vector administration.
Figure 5 Photomicrograph of ␤-galactosidase stained liver 10 days following combined T3 and dHGF injection and peripheral venous administration of the TELCeB/AF-7/DOGS complex. There are transduced hepatocytes scattered throughout the hepatic parenchyma except in the perivenous areas around the central hepatic veins (HV). Original magnification 40×.
Gene Therapy
We and others have investigated growth factors as an alternative way of inducing liver proliferation without preceding liver damage. The prior administration of a number of the growth factors including T3 and dHGF has enabled the transduction, albeit at a low level, of the undamaged liver by retroviral vectors. 16, 17, 19 HGF has been used to transduce the rat liver efficiently but this required a 5 day infusion of both the growth factor and retroviral vector. 20 Given that T3 and HGF work by different intracellular mechanisms, we hypothesised that further significant increases in cell proliferation might be achieved by their co-administration. The thyroid axis is essential to liver regeneration; thyroidectomized rats fail to regenerate their livers following partial hepatectomy, 23 and exogenously administered T3 can cause a repeatable surge of DNA synthesis in the intact livers of euthyroid rats. 24 T3 acts via hormone responsive nuclear transcription factors present in most tissues and regulates the expression of numerous genes. [25] [26] [27] [28] [29] HGF is an important mitogen, motogen and morphogen for hepatocytes. [30] [31] [32] [33] [34] Serum levels of HGF rise rapidly after partial hepatectomy and precede the surge in hepatic DNA synthesis. 35 HGF binds to the receptor protein tyrosine kinase c-Met and switches on cell proliferation through the mitogen-activated protein kinase (MAPK) pathway. 31 We used a recombinant form of a naturally occurring truncated variant of HGF, dHGF, which lacks a five amino acid sequence in the first kringle domain, and has a greater potency than the fulllength HGF molecule in stimulating DNA synthesis in rat hepatocytes. 36 An additional advantage of using this was that the pharmacokinetics and pharmacological effects of this preparation of dHGF after intravenous injection in rats have been fully described. 37 We confirmed that co-administration of these two growth factors stimulated hepatocyte proliferation more effectively than either growth factor alone and found significant synergy of action between the two growth factors.
It is of interest that the hepatocytes stimulated by the two growth factors differ slightly in their location. Those stimulated by dHGF were mainly in the periportal area and mid-zonal regions, the zones which respond first after partial hepatectomy, whereas T3 preferentially stimulated mid-zonal cells. We demonstrated that the effect of the two growth factors was synergistic rather than simply additive implying that there are cells capable of responding to both mitogens.
We considered the appeal of increasing the number of cells that were undergoing cell division, and thus available for retroviral infection, combined with a technique to increase vector infectivity. There are a number of compounds that increase retroviral infectivity in vitro. The most commonly used compound is the polycation Polybrene, which unfortunately is toxic and inappropriate for in vivo use. We have used the commercially available cationic liposome DOGS as an additive to an amphotropic pseudotyped retroviral vector to increase its in vivo infectivity. The mechanism of action of the liposomes is probably through reducing the repulsive forces between the virus particle and the negatively charged surface of the cell, but transduction remains limited to mitotically active cells. 12 It is possible that the liposome aids the hepatocyte targeting of the construct after peripheral venous administration, but this possibility was not directly investigated.
As predicted, the level of hepatocyte transduction correlated with the degree of hepatocyte proliferation at the time of vector administration, and differences in location of the proliferating hepatocytes were mirrored by the distribution of the transduced hepatocytes. The semisynchronous response of hepatocytes to growth factor stimulation suggested that repeated vector administration would be beneficial. We demonstrated, using equal volumes of vector, that more efficient liver transduction was obtained by splitting the vector's administration over time. Peripheral venous administration of the vector is clinically desirable as it is less invasive and allows repetition. With current vector technology repeat liver transduction may indeed be required, since retroviral transgenes are commonly silenced by promoter methylation in vivo. 38 Long-term expression is an important though separate issue from the aims of this study that were to maximise hepatocyte proliferation and transduction. It is expected that future improvements in vector technology (eg tissuespecific promoters may circumvent the problem of shortterm expression) may allow more permanent gene expression in vivo.
In conclusion, we have shown that up to 7% of hepatocytes can be transduced in vivo via the portal route with retroviral vectors without the requirement for preceding liver damaging surgery. Via the peripheral venous route, without any requirement to access or modify liver blood flow, over 4% of hepatocytes can be transduced. Although a lower proportion of hepatocytes are transduced than has been reported by us in the post-hepatectomy liver, 12 it should be remembered that there are only a third as many hepatocytes in the post-hepatectomy liver remnant. We have demonstrated that the liver can be simply and conveniently transduced in vivo by an integrating gene vector system, indicating clinically applicable techniques of in vivo hepatic gene therapy.
Materials and methods
Animals
Male Wistar rats weighing 200-250 g were used. They were housed in a temperature and light controlled room (12 h light/dark cycle) and were allowed water and food ad libitum.
Induction of hepatocyte proliferation T3 (Sigma-Aldrich Co Ltd, Poole, UK) was injected subcutaneously, dHGF was injected intravenously. T3 was dissolved in 100 ml of 0.01 m NaOH in 0.9 m NaCl. dHGF was kindly supplied by Snow Brand Milk Products Co Ltd (Tochigi Japan), and was dissolved in 0.9 m NaCl.
Measurement of hepatocyte proliferation
To estimate the proportion of cells in DNA synthesis at any one time, BrdU was administered intraperitoneally (50 mg/kg) 1 h before death.
Generation of high-titre amphotropic retrovirus stocks TELCeB/AF-7 cells were used to generate high titres of amphotropic retrovirus stocks. This is a high-titre replication-defective vector encoding the gene for ␤-galactosidase together with a nuclear localisation signal. 21 Cells were grown in DMEM supplemented with 10% foetal calf serum at 37°C. To prepare viruses, cells were grown to confluency and refed with fresh serum containing medium overnight. The following day virus containing supernatants were harvested and filtered through 0.4 m filters. Viruses were concentrated by ultrafiltration using Macrosep tubes (300K, Flowgen, Staffordshire, UK) centrifuged at 3000 g before determination of retrovirus titre and helper virus assay. These were determined on NIH3T3 cells using serial dilutions of virus. In the presence of polybrene, the concentrated virus was titred at 1 × 10 8 IU/ml without evidence of helper virus contamination. In the presence of DOGS, virus titre was determined as 1 × 10 9 IU/ml.
Retrovirus/amphiphile complex formation To generate virosome complexes for titration a 20 l aliquot of virus stock was added to 0.5 ml of serum-free DMEM plus the appropriate amount of amphiphile and incubated for 30 min at room temperature to allow complex formation to occur. For titre estimation each respective complex was prepared in 3 ml with 10% serum containing medium then added to NIH3T3 cells and left for 24 h for infection to occur. Virus stocks were complexed with DOGS at 5 mg/ml for 30 min before in vivo use.
Transduction of the rat liver in vivo with retroviral vectors A modified method of Rettinger et al 10 was used to transduce the liver. Under isoflurane anaesthetic a midline laparotomy was performed. The bowels were wrapped in a saline-soaked swab and reflected to the left. The hepatic artery and portal vein were identified and clipped using micro-aneurysm clips. The portal vein was then cannulated and 1 ml TELCeB/AF-7/DOGS complex was injected over 5 min. Homeostasis was achieved through direct pressure with topical thrombin. Animals were allowed to recover in a warm, quiet environment. For peripheral vein injection of the vector 0.5 ml or 1 ml of TELCeB/AF-7/DOGS complex was injected via tail vein as a bolus.
Tissue harvest Animals were killed by exsanguination under isoflurane anaesthesia. The liver and other organs were removed. Tissue for histochemical processing was frozen immediately in isopentane and liquid nitrogen. Tissue for immunostaining was fixed in Methacarn (60% methanol, 30% chloroform, 10% glacial acetic acid) before routine histological processing and embedding in wax blocks.
Immunocytochemistry and histochemistry
For immunocytochemical analysis 4 m thick sections were used. The incorporation of bromodeoxyuridine (Sigma, St Louis, MO, USA) into hepatic nuclei was detected using a mouse monoclonal antibody (DAKO, Glostrup, Denmark), followed by a biotinylated rabbit anti-mouse secondary antibody (DAKO). Visualisation was achieved by the indirect peroxidase technique using diaminobenzidine tetrahydrochloride dihydrate (Aldrich Chemical, Milwaukee, WI, USA) as a substrate.
To analyse the tissue expression of the ␤-galactosidase transgene 10 m frozen tissue sections were cut on to glass slides, fixed in a solution of 1.25% glutaraldehyde at 4°C for 5 min, washed with PBS then covered in X-gal (Gibco BRL, Grand Island, NY, USA) solution (1 mg/ml, pH 7.4) and incubated overnight at 37°C. Sections were then washed in PBS, counterstained lightly with eosin or carmalum stain, dehydrated and mounted in pertex (Cellpath, Hemel Hempstead, UK).
Quantification procedures
The BrdU labelling index and the proportion of hepatocytes expressing nuclear ␤-galactosidase was determined by counting 2000 hepatocyte nuclei per section from consecutive light microscopy fields. The specificity of staining was confirmed by examining serial sections of liver.
